Evaluation of different antiandrogenic progestins on clinical and biochemical variables in polycystic ovary syndrome

References

• De Leo V, Musacchio MC, Cappelli V, et al. Genetic, hormonal and metabolic aspects of PCOS: an update. Reprod Biol Endocrinol. 2016;14:38.
   PubMed Web of Science ®Google Scholar
• Raudrant D, Rabe T. Progestogens with antiandrogenic properties. Drugs. 2003;63:463–492.
   PubMed Web of Science ®Google Scholar
• Nader S, Diamanti-Kandarakis E. Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis. Hum Reprod. 2007;22:317–322.
   PubMed Web of Science ®Google Scholar
• Charitidou C, Farmakiotis D, Zournatzi V, et al. The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome. Atherosclerosis. 2008;196:958–965.
   PubMed Web of Science ®Google Scholar
• Melo A, Reis R, Ferriani R, et al. Hormonal contraception in women with polycystic ovary syndrome: choices, challenges, and noncontraceptive benefits. Open Access J Contracept. 2017;Volume 8:13–23.
   Web of Science ®Google Scholar
• Amiri M, Ramezani Tehrani F, Nahidi F, et al. Comparing the effects of combined oral contraceptives containing progestins with low androgenic and antiandrogenic activities on the hypothalamic–pituitary–gonadal axis in patients with polycystic ovary syndrome: systematic review and meta-analysis. JMIR Res Protoc. 2018;7:e113.
   PubMed Web of Science ®Google Scholar
• Spritzer PM, Barone CR, Oliveira FB. Hirsutism in polycystic ovary syndrome: pathophysiology and management. Curr Pharm Des. 2016;22:5603–5613.
   PubMed Web of Science ®Google Scholar
• Falsetti L, Gambera A, Tisi GC. Efficacy of the combination ethinyl oestradiol and cyproterone acetate on the endocrine, clinical and ultrasonographic profile in polycystic ovarian syndrome. Hum Reprod. 2001;16:36–42.
   PubMed Web of Science ®Google Scholar
• Falsetti L. Sex hormone-binding globulin during treatment with various combined oral contraceptives. Gynecol Obstet. 1988;2:131–136.
   Google Scholar
• De Leo V, Morgante G, Piomboni P, et al. Evaluation of effects of an oral contraceptive containing ethinylestradiol combined with drospirenone on adrenal steroidogenesis in hyperandrogenic women with polycystic ovary syndrome. Fertil Steril. 2007;88:113–117.
   PubMed Web of Science ®Google Scholar
• Amiri M, Ramezani Tehrani F, Nahidi F, et al. Effects of oral contraceptives on metabolic profile in women with polycystic ovary syndrome: a meta-analysis comparing products containing cyproterone acetate with third generation progestins. Metabolism. 2017;73:22–35.
   PubMed Web of Science ®Google Scholar
• Yildizhan R, Gokce AI, Yildizhan B, et al. Comparison of the effects of chlormadinone acetate versus drospirenone containing oral contraceptives on metabolic and hormonal parameters in women with PCOS for a period of two-year follow-up. Gynecol Endocrinol. 2015;31:396–400.
   PubMed Web of Science ®Google Scholar
• Druckmann R. Profile of the progesterone derivative chlormadinone acetate – pharmocodynamic properties and therapeutic applications. Contraception. 2009;79:272–281.
   PubMed Web of Science ®Google Scholar
• De Leo V, Musacchio MC, Cappelli V, et al. Hormonal contraceptives: pharmacology tailored to women’s health. Hum Reprod Update. 2016;22:634–646.
   PubMed Web of Science ®Google Scholar
• Bartsch V. Gynecological uses of dienogest alone and in combination with oestrogens. J Med Drug Rev. 2015;5:1–31.
   Google Scholar
• Oettel M, Breitbarth H, Elger W, et al. The pharmacological profile of dienogest. Eur J Contracept Reprod Health Care. 1999;4:2–13.
   Google Scholar
• Ruan X, Seeger H, Mueck AO. The pharmacology of dienogest. Maturitas. 2012;71:337–344.
   PubMed Web of Science ®Google Scholar
• Regidor PA, Schindler AE. Antiandrogenic and antimineralocorticoid health benefits of COC containing newer progestogens: dienogest and drospirenone. Oncotarget. 2017;8:83334–83342.
   PubMedGoogle Scholar
• Kuhl H. Comparative pharmacology of newer progestogens. Drugs. 1996;51:188–215.
   PubMed Web of Science ®Google Scholar
• Oettel M, Graser T, Hoffman H. Why dienogest as a progestogenic component of postmenopausal nonandrogenic hormone replacement therapy? Drugs Today. 2001;37:3–15.
   Web of Science ®Google Scholar
• Stolzner W, Kurischko A, Freund R, et al. Tierexperimentell-endokrinologische Charakterisierung des Gestagens Dienogest (STS 557). II Antigonadotrope, gestagene, androgene und antiandrogene Wirkungen. In: Stech D, Carol W, eds. Proceedings des III. Jenaer Symposiums zur hormonalen Kontrazeption. Jena: Friedrich-Schiller-Universität Jena; 1985. p. 165–182.
   Google Scholar
• De Leo V, Di Sabatino A, Musacchio MC, et al. Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome. Contraception. 2010;82:276–280.
   PubMed Web of Science ®Google Scholar
• The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41–47.
   PubMed Web of Science ®Google Scholar
• Van Rooijen M, Silveira A, Hamsten A, et al. Sex hormone-binding globulin – a surrogate marker for the prothrombotic effects of combined oral contraceptives. Am J Obstet Gynecol. 2004;190:332–337.
   PubMed Web of Science ®Google Scholar
• van Vliet HA, Rosendaal FR, Rosing J, Helmerhorst FM. Sex hormone-binding globulin: an adequate surrogate marker for venous thromboembolism in women using new hormonal contraceptives. Contraception. 2009;79:328–329; author reply 329–30.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Medical eligibility criteria for contraceptive use. 5th ed. Geneva: WHO; 2015.
   Google Scholar
• Grimes D, Stuart G, Levi E. Screening women for oral contraception: can family history identify inherited thrombophilias. Obstet Gynecol. 2012;120:889–895.
   PubMed Web of Science ®Google Scholar
• Zimmermann T, Dietrich H, Wisser KH, et al. The efficacy and tolerability of Valette: a postmarketing surveillance study. Eur J Contracept Reprod Health Care. 1999;4:155–164.
   PubMed Web of Science ®Google Scholar
• Somigliana F, Vigano P, Barbara G, et al. Treatment of endometriosis related pain: options and outcomes. Front Biosci. 2009;1:455–465.
   Google Scholar
• Caruso S, Iraci M, Cianci S, et al. Effects of long-term treatment with dienogest on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain. J Pain Res. 2019;12:2371–2378.
   PubMed Web of Science ®Google Scholar
• Wiegratz I, Stahlberg S, Manthey T, et al. Effects of combined oral contraceptive ethinylestradiol (30 μg) and dienogest (2 mg) on carbohydrate metabolism during 1 year of conventional or extended-cycle use. Horm Metab Res. 2010;42:358–363.
   PubMed Web of Science ®Google Scholar
• De Leo V, Fruzzetti F, Musacchio MC, et al. Effect of a new oral contraceptive with estradiol valerate/dienogest on carbohydrate metabolism. Contraception. 2013;88:364–368.
   PubMed Web of Science ®Google Scholar
• Cianci A, Panella M, Fichera M, et al. d-chiro-Inositol and alpha lipoic acid treatment of metabolic and menses disorders in women with PCOS. Gynecol Endocrinol. 2015;31:483–486.
   PubMed Web of Science ®Google Scholar
• La Marca A, Grisendi V, Dondi G, et al. The menstrual cycle regularization following d-chiro-inositol treatment in PCOS women: a retrospective study. Gynecol Endocrinol. 2015;31:52–56.
   PubMed Web of Science ®Google Scholar
• Reyes-Muñoz E, Sathyapalan T, Rossetti P, et al. Polycystic ovary syndrome: implication for drug metabolism on assisted reproductive techniques – a literature review. Adv Ther. 2018;35:1805–1815.
   PubMed Web of Science ®Google Scholar
• Cappelli V, Musacchio MC, Bulfoni A, et al. Natural molecules for the therapy of hyperandrogenism and metabolic disorders in PCOS. Eur Rev Med Pharmacol Sci. 2017;21:15–29.
   PubMed Web of Science ®Google Scholar
• Fruzzetti F, Perini D, Fornaciari L, et al. Discontinuation of modern hormonal contraceptives: an Italian survey. Eur J Contracept Reprod Health Care. 2016;21:449–454.
   PubMed Web of Science ®Google Scholar